NCT02947620View on ClinicalTrials.gov

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions
Type II DiabetesDyslipidemia
Interventions
DRUG

Metformin/Atorvastatin 1500mg/40mg, QD

DRUG

Metformin 1500mg, QD

DRUG

Atorvastatin 40mg, QD

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY